Results

Total Results: 2,208 records

Showing results for "drug".

1781. Medical Therapies for Locally Advanced Gastric Adenocarcinoma (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/gastric-cancers-protocol-amended.pdf
      February 07, 2025 - National Institutes of Health [NIH], Agency for Healthcare Research and Quality [AHRQ], Food and Drug … ipilimumab OR nivolumab OR opdivo OR pembrolizumab OR keytruda OR sintilimab OR tecentriq OR yervoy) 7 'drug

1782. Evidence-based Practice Center Systematic Review Protocol (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/chronic-kidney-disease-anemia-2011_research-protocol.pdf
      January 01, 2011 - Food and Drug Administration databases. … Transferrin/ad, an, bl, du, de, me, pk, tu [Administration & Dosage, Analysis, Blood, Diagnostic Use, Drug

1783. Laboratory Biomarkers for Iron Deficiency Anemia in Late Stage Chronic Kidney Disease | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/chronic-kidney-disease-anemia-2011/research-protocol
      December 01, 2019 - Food and Drug Administration databases. … , bl, du, de, me, pk, tu [Administration & Dosage, Analysis, Blood, Diagnostic Use, Drug

1784. Progression-Free Survival: What Does It Mean for Psychological Well-Being or Quality of Life? | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/survival-quality/research
      November 01, 2017 - In comparison to overall survival (OS), the gold standard for cancer drug evaluation, PFS can be evaluated … the primary outcome measure being used to establish the performance (efficacy and safety) of a new drug

1785. Newer Medications for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/prostatic-hyperplasia-medications_research-protocol.pdf
      April 21, 2015 - In the early 1990s, the Federal Drug Administration (FDA) approval of medications for BPH shifted LUTS … prostates with either agent are supported by systematic reviews.10, 13 Recently, newer drugs and other drug … Common medications used to treat LUTS associated with BPH Drug class - Mechanism of action Medication … , drug manufacturer, device trade name, keyword] 109. exp Product Surveillance, Postmarketing/ 110 … . exp "Drug-Related Side Effects and Adverse Reactions"/ 111. exp Adverse Drug Reaction Reporting Systems

1786. Minimal Modeling Approaches to Value of Information Analysis for Health Research (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/methods-future-value-of-information_research.pdf
      June 01, 2011 - Drug Topics Red Book. Montvale, NJ: Thomson Healthcare; 2010. 43. … Third-party payer Third-party payer Data - Symptom resolution: Comparative effectiveness study [41) - Drug … price: Drug Topics Red Book (42) - Survival curves: Phase III trial (46) - Costs: assumptions

1787. Disposition of Comments for Technical Brief 27 Patient Safety (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/ambulatory-safety_disposition-comments.pdf
      October 19, 2016 - Outpatient drug safety: new steps in an old direction. … Pharmacoepidemiol Drug Saf. 2007 Feb;16(2):160-5). … seems overly limiting especially when the panel would allow for interventions in which potential drug … requirement, it appears to erroneously exclude studies involving relevant issues such as “potential drug

1788. Technical Brief: Use and Safety of Positional MRI in the Management of Patients with Musculoskeletal Pain | Effective Health Care (EHC) Program
      effectivehealthcare-admin.ahrq.gov/products/musculoskeletal-disorders-imaging/research-protocol
      December 01, 2019 - What is the current the Food and Drug Administration (FDA) clearance status of these positional MRI machines

1789. Diagnosis and Management of Gout: Current State of the Evidence (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/gout_clinician.pdf
      January 01, 2017 - overall adverse events ��� Subgroup of 1 RCT 2269 Age and race do not affect the efficacy of either drug … include toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), bone marrow suppression, and drug

1790. Disposition of Comments Report for Recurrent Nephrolithiasis in Adults (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/kidney-stone-prevention_disposition-comments.pdf
      July 26, 2012 - This is impractical and for all intents and purposes, this drug is not available in the US.

1791. Binge-Eating Research-Protocol (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/binge-eating_research-protocol.pdf
      July 21, 2014 - Drug Alcohol Depend. 2008 Jan 11;93(1- 2):12-20. Epub: 2007/10/19. PMID: 17942244. 16.

1792. Disposition of Comments_Comparative Effectiveness Review No. 262_Pharmacotherapy for Adults With Alcohol Use Disorder in Outpatient Settings: Systematic Review (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cer-262-pharmacotherapy-alcohol-disposition-comments.pdf
      November 07, 2023 - effect is apparently due to a wish to avoid an unpleasant experience and not a direct effect of the drug … Since the research subject does not know whether they've received placebo or active drug, both treatment

1793. Hemorrhage-Postpartum Executive (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/hemorrhage-postpartum_executive.pdf
      April 01, 2015 - 1 Comparative Effectiveness Review Number 151 Management of Postpartum Hemorrhage Executive Summary Introduction Postpartum hemorrhage (PPH) is commonly defined as blood loss exceeding 500 mL following vaginal birth and 1,000 mL following cesarean.1 Definitions vary, however, and diagnosis of PPH is subjectiv…

1794. Nonopioid Pharmacologic Treatments for Chronic Pain: Appendix E (xls file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/nonopioid-chronic-pain-ape_0.xlsx
      August 08, 2017 - myocardial infarction; NA = not applicable; NR = not reported; NSAID = nonsteroidal anti-inflammatory drug … rate ratio; SMD: standardized mean difference; tNSAID = traditional nonsteroidal anti-inflammatory drug

1795. CER 45 Self-Measured Blood Pressure Monitoring Comparative Effectiveness Surveillance Final 4.7.16 (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/measuring-blood-pressure-surveillance-160412.pdf
      April 11, 2016 - Food"and"Drug"Administration"(FDA),"Health"Canada,"and" Medicines"and"Healthcare"Products"Regulatory"Agency … situations"where"a"limited"search"would"produce"prima"facie"evidence"that"a"conclusion" was"out"of"date,"such"as"the"withdrawal"of"a"drug"or"surgical"device"from"the"market … trial),$medication$number$and$dosage$(five$trials),$ medication$adherence$(three$trials),$and$adverse$drug … $medication$ number$and$dosage$(in$11$ trials),$medication$adherence$ (in$6$trials),$and$adverse$drug … medication$number$and$ dosage$(five$trials),$ medication$adherence$(three$ trials),$and$adverse$drug

1796. Disposition of Comments Report for Enzyme-Replacement Therapies for Lysosomal Storage Disease (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/lysosomal-storage-diseases-therapies_disposition-comments.pdf
      January 01, 2014 - The purpose of a Technical Brief is to provide an overview of the evidence for a technology, drug … It is treated with a FDA approved drug, Cystagon. This is nowhere in your document. 2. … 6 Para 3 In the third paragraph of page 6, we believe that the reference to an “average annual drug … Drug shortages: the author alludes to shortages in Europe and Australia, but shortages were a severe … article only if we used the text phrase “enzyme replacement therapy” OR “ERT”, or the subheading “drug

1797. #06 Developmental Delays ADHD, and Autism (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/06_devdelays_autism_potential_high_impact_june_2012.pdf
      January 01, 2012 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug

1798. Methods Research Report - Framework for Determining Research Gaps During Systematic Review: Evaluation (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/research-gaps_research.pdf
      February 01, 2013 - Problems or Issues JHU Response G SR For the review I used, we had many, many comparisons (22 drug-drug

1799. Psoriasis-Chronic Executive (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/psoriasis-chronic_executive.pdf
      November 01, 2012 - etanercept, and adalimumab), and one anti-IL 12/23 agent (ustekinumab) have approval from the Food and Drug … agents concluded a difference in efficacy, suggesting heterogeneity within the class and indicating drug … and therefore do not make between-class comparisons, rather limit comparisons with the individual drug … systemic biologic agents and systemic nonbiologic agents (between-class comparisons on an individual drug … systemic biologic agents and systemic nonbiologic agents (between-class comparisons on an individual drug

1800. Evidence Report on the (pdf file)
      effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/antidepressants-update_research-protocol.pdf
      July 13, 2011 - , continuation phase) or recurrence (i.e., maintenance phase) when a patient 1) continues the drug … medications with new formulations (such as an extended release formulation) are approved by the Food and Drug … Administration (FDA) through an application called a supplemental new drug application (sNDA). … interest is whether response or remission can be maintained if patients who have responded to one drug … If fewer than three head-to-head trials are available for any drug comparison, we will compute indirect